IBSA USA
Emily Lewis, MS, RD, is a seasoned professional in the field of nutrition and pharmaceutical sales, currently serving as a Specialty Pharmaceutical Sales Representative at IBSA USA since August 2021. Prior to this role, Emily held positions as a Clinical Sales Consultant at Ardelyx, Inc. and a Renal Dietitian at Us Renal Care. Emily's background includes experience as a Registered Dietitian at DaVita Kidney Care and as a Kidney Transplant Dietitian at St. Luke's Health. Emily also contributed as a Graduate Teaching Assistant and Dietetic Intern at Texas Woman's University after earning a Bachelor of Science in Dietetics and Clinical Nutrition Services from Auburn University and a Master of Science in Dietetics and Clinical Nutrition Services from Texas Woman's University.
This person is not in any teams
IBSA USA
IBSA USA is the subsidiary of IBSA Group, the largest privately owned pharmaceutical company in Switzerland. IBSA is committed to improving patient quality of life through research, innovation, and the development of effective drugs and cutting-edge technologies. IBSA USA markets two unique levothyroxine formulations in the U.S. for the treatment of hypothyroidism: Tirosint® (levothyroxine sodium) capsules and Tirosint®-SOL (levothyroxine sodium) oral solution. IBSA also markets Licart™ (diclofenac epolamine) topical system 1.3%, the only once-a-day topical nonsteroidal anti-inflammatory (NSAID) available in the U.S. to treat acute pain due to minor strains, sprains, and contusions. IBSA is focused on the health and well-being of patients and driven by the desire to bring therapeutic alternatives to as many people as possible. IBSA Group bases its philosophy on four sustainable pillars: Person, Innovation, Quality, and Responsibility. For more information about Tirosint, Tirosint-SOL, or Licart, including Full Prescribing Information, go to each brand’s respective website.